Abstract:
수용성 무기염 (A)와 왁스 (B)를 포함하고, 이 때 이들 성분은 물에 용해되거나 분산되며 그 고체 농도비(중량비) (B)/(A)는 0.3 내지 1.5인 것이 특징인 금속 재료의 소성 가공용 수성 윤활제 및, 그 위에 화학적 가공층이 제공되지 않은 금속 재료의 표면위에 수성 윤활제를, 바람직하게는 0.5 내지 40g/m 2 의 건조 중량으로 도포시키고, 이어서 건조시킴으로써 윤활성 피막을 제조하는 것을 특징으로 하는 윤활성 피막의 형성 방법. 바람직하게도 수성 윤활제는 추가로 지방산의 금속염 (C)를, 0.01 내지 0.4의 고체 농도비 (C)/(A)로 포함한다. 수용성 무기염 (A)는 술페이트, 실리케이트, 보레이트, 몰리브데이트 및 텅스테이트 중에서 선택되는 것이 바람직하다. 바람직하게도 왁스는 물에 분산되며 70 내지 150℃의 용해점을 갖는다. 지방산의 금속염 (C)는 12 내지 26개의 탄소 원자를 갖는 포화 지방산과 아연, 칼슘, 바륨, 알루미늄, 마그네슘 및 리튬 중에서 선택된 금속을 반응시켜 얻는 것이 바람직하다. 화학적 가공층이 형성되지 않은 금속 표면에 우수한 윤활성을 용이하게 부여하기 위해 본 수성 윤활제를 사용할 수 있다.
Abstract:
This invention relates to the use of ionic liquids as lubricants in vapor compression systems for cooling. This invention also relates to an apparatus for adjusting the temperature that operates a vapor compression cycle.
Abstract:
A process for drawing wire employing a lubricant comprising perfluorocarbon compounds (PFCs), including aliphatic perfluorocarbon compounds ( alpha -PFCs) having the general formula CnF2n+2, perfluoromorpholines having the general formula CnF2n+1ON, perfluoroamines (PFAs) and highly fluorinated amines (HFAs), and perfluoroethers (PFEs). Such fully and highly fluorinated carbon compounds exhibit a very high degree of thermal and chemical stability due to the strength of the carbon-fluorine bond. Further, because the compounds are fully fluorinated, and therefore do not contain chlorine and bromine, they have zero ozone depletion potential (ODP). Further, because the compounds are photochemically non-reactive in the atmosphere, they are not precursors to photochemical smog and are exempt from the United States Environmental Protection Agency (EPA) volatile organic compound (VOC) definition. Further, because they are volatile, the compounds are easily removed at the end of the process without need for an additional cleaning step. The process provides wire at significantly higher production speeds and longer die life with improved quality and less byproduct debris.
Abstract:
The invention describes an apparatus having an evacuable cavity surrounded by a casing, there being arranged in the cavity and/or on the casing, and projecting into the cavity, at least one friction assembly and/or bearing assembly having at least two elements each having a surface, the two surfaces interacting, and at least one of the two surfaces being coated with a lubricating varnish, at least in the region of their interaction, the varnish comprising a polymeric binder and also molybdenum disulphide (MoS2) and graphite as solid lubricants. The invention further describes an anti-friction paste, an anti-friction dispersion, and the use of a lubricating varnish under high or ultra-high vacuum.
Abstract:
Disclosed is a lubricating oil which has a low viscosity and a low vapor pressure at the same time, is free from a risk of inflammation and excellent in heat resistance. The lubricating oil has friction characteristics equivalent to those of the conventional hydrocarbon lubricating oils, and can be used for a long time under extremely severe conditions such as at high temperatures in vacuum condition. The lubricating oil contains, as a base oil, an ionic liquid which is composed of cations and anions and has an ion concentration of not less than 1 mol/dm3.
Abstract:
The invention provides a lube oil which exhibits low vapor pressure despite having low viscosity, is non-flammable, exhibits excellent heat resistance, has tribological characteristics equivalent to those of conventional hydrocarbon-based lube oils, and can be used for a long time under very severe conditions such as high temperature and vacuum. The lube oil contains, as a base oil, an ionic liquid formed of a cation and an anion and having an ion concentration of 1 mol/dm 3 or more.
Abstract:
A method for treatment of bacterial infections with rifalazil administered once-weekly, or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.